x NoneEntity Type
0001601485
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Angion Biomedica Corp.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Angion Biomedica Corp. 
Street Address 1Street Address 2
 51 CHARLES LINDBERGH BOULEVARD 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 UNIONDALE NEW YORK 11553 (516) 326-1200 



3. Related Persons
Last NameFirst NameMiddle Name
GoldbergItzhakD.
Street Address 1Street Address 2
51 Charles Lindbergh Boulevard
CityState/Province/CountryZIP/Postal Code
UniondaleNEW YORK11553
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Chairman

Last NameFirst NameMiddle Name
VenkatesanJayR.
Street Address 1Street Address 2
51 Charles Lindbergh Boulevard
CityState/Province/CountryZIP/Postal Code
UniondaleNEW YORK11553
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Chief Executive Officer

Last NameFirst NameMiddle Name
YaminMichael
Street Address 1Street Address 2
51 Charles Lindbergh Boulevard
CityState/Province/CountryZIP/Postal Code
UniondaleNEW YORK11553
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GanziVictor
Street Address 1Street Address 2
51 Charles Lindbergh Boulevard
CityState/Province/CountryZIP/Postal Code
UniondaleNEW YORK11553
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   x Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2019-12-24 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities x Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 10000 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 GP Nurmenkari Inc. 153480
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 22 Elizabeth Street SONO Square, Suite 1J
City State/Province/CountryZIP/Postal Code
 Norwalk CONNECTICUT 06854
State(s) of Solicitation x All States o Foreign/Non-US
 

RecipientRecipient CRD Number o None
 T.R. Winston & Company, LLC 10571
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 2049 Century Park East Suite 320
City State/Province/CountryZIP/Postal Code
 Los Angeles CALIFORNIA 90067
State(s) of Solicitation x All States o Foreign/Non-US
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 12000000 USD o Indefinite
Total Amount Sold $ 6081980 USD 
Total Remaining to be Sold $ 5918020 USD o Indefinite
 
Clarification of Response (if Necessary)
 Company and Placement Agents may increase total offering amount.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 51


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 563200 USD x Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
 Assumes offering is fully subscribed. Each placement agent ("PA") will also receive warrants equal to 10% of the total amount of notes sold by such PA divided by $15.


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Angion Biomedica Charts.
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Angion Biomedica Charts.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ANGN Message Board. Create One! See More Posts on ANGN Message Board See More Message Board Posts

Angion Biomedica Corp. News

Loading Messages....

More Angion Biomedica Corp. News Articles